Screening and prevention of hepatitis C virus reactivation during chemotherapy

被引:8
作者
Li, Yuan-Rung [1 ]
Hu, Tsung-Hui [2 ]
Chen, Wen-Chi [3 ]
Hsu, Ping-, I [4 ]
Chen, Hui-Chun [5 ,6 ]
机构
[1] Kaohsiung Vet Gen Hosp, Dept Internal Med, Kaohsiung 813, Taiwan
[2] Chang Gung Univ, Dept Internal Med, Coll Med, Kaohsiung 833, Taiwan
[3] Kaohsiung Vet Gen Hosp, Dept Internal Med, Div Gastroenterol & Hepatol, Kaohsiung 813, Taiwan
[4] China Med Univ, Dept Internal Med, An Nan Hosp, Div Gastroenterol & Hepatol, 66,Sec 2,Changhe Rd, Tainan 709, Taiwan
[5] Kaohsiung Chang Gung Mem Hosp, Dept Radiat Oncol, Kaohsiung 833, Taiwan
[6] Chang Gung Univ, Coll Med, Kaohsiung 833, Taiwan
关键词
Hepatitis C virus; Chemotherapy; Screening; Reactivation; Hepatitis flare; PATIENTS RECEIVING CHEMOTHERAPY; ACUTE EXACERBATION; FULMINANT-HEPATITIS; LIVER DYSFUNCTION; B-VIRUS; INFECTION; THERAPY; LEUKEMIA; CHILDREN;
D O I
10.3748/wjg.v27.i31.5181
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Hepatitis C virus (HCV) reactivation occurs in 23% of HCV-infected cancer patients receiving chemotherapy. Forty-three percent of the patients with reactivation of HCV during chemotherapy develop a hepatitis flare. Most of the cancer patients with HCV reactivation have an unremarkable clinical course following an HCV-related hepatitis flare during chemotherapy. However, 26%-57% of the cancer patients developing an acute flare of chronic hepatitis C during chemotherapy require unanticipated discontinuation or dose reduction of chemotherapy, which results in deleterious changes in the cancer treatment plan. Although an optimal strategy for HCV screening in cancer patients receiving chemotherapy has not been established, universal pre-chemotherapy HCV testing for patients with hematological malignancies is recommended by current guidelines. All the currently approved direct-acting antivirals (DAAs) can be used in cancer patients, but the use of DAAs during chemotherapy should avoid drug-drug interactions between chemotherapy and antiviral agents. If there are no contraindications or anticipated drug-drug interactions, DAAs treatment can be administered before, during, or after chemotherapy. In conclusion, HCV reactivation occurs in approximately one-fourth of HCV-infected cancer patients receiving chemotherapy. An HCV-related hepatitis flare during chemotherapy may lead to the discontinuation of potentially life-saving chemotherapy. Currently, universal HCV screening is recommended in hematological malignancy patients before chemotherapy, but there is no evidence-based guideline for other cancer patients. DAAs treatment can cure HCV infection and prevent HCV reactivation during chemotherapy.
引用
收藏
页码:5181 / 5188
页数:8
相关论文
共 31 条
[1]   Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection [J].
Ghany M.G. ;
Morgan T.R. .
HEPATOLOGY, 2020, 71 (02) :686-721
[2]   Increased incidence of cancer and cancer-related mortality among persons with chronic hepatitis C infection, 2006-2010 [J].
Allison, Robert D. ;
Tong, Xin ;
Moorman, Anne C. ;
Ly, Kathleen N. ;
Rupp, Loralee ;
Xu, Fujie ;
Gordon, Stuart C. ;
Holmberg, Scott D. .
JOURNAL OF HEPATOLOGY, 2015, 63 (04) :822-828
[3]  
[Anonymous], 1994, IARC MONOGRAPHS EVAL
[4]   INCIDENCE AND MORBIDITY OF INFECTION BY HEPATITIS-C VIRUS IN CHILDREN WITH ACUTE LYMPHOBLASTIC-LEUKEMIA [J].
DIBENEDETTO, SP ;
RAGUSA, R ;
SCIACCA, A ;
DICATALDO, A ;
MIRAGLIA, V ;
DAMICO, S ;
LONIGRO, L ;
IPPOLITO, AM .
EUROPEAN JOURNAL OF PEDIATRICS, 1994, 153 (04) :271-275
[5]   EASL Recommendations on Treatment of Hepatitis C 2018 [J].
Pawlotsky J.-M. ;
Negro F. ;
Aghemo A. ;
Berenguer M. ;
Dalgard O. ;
Dusheiko G. ;
Marra F. ;
Puoti M. ;
Wedemeyer H. .
JOURNAL OF HEPATOLOGY, 2018, 69 (02) :461-511
[6]   HEPATITIS-C VIRUS-INFECTION IN PATIENTS WITH LEUKEMIA [J].
FUJII, Y ;
KAKU, K ;
TANAKA, M ;
YOSIZAKI, M ;
KANEKO, T ;
MATUMOTO, N .
AMERICAN JOURNAL OF HEMATOLOGY, 1994, 46 (04) :278-282
[7]   Antiviral therapy improves overall survival in hepatitis C virus-infected patients who develop diffuse large B-cell lymphoma [J].
Hosry, Jeff ;
Mahale, Parag ;
Turturro, Francesco ;
Miranda, Roberto N. ;
Economides, Minas P. ;
Granwehr, Bruno P. ;
Torres, Harrys A. .
INTERNATIONAL JOURNAL OF CANCER, 2016, 139 (11) :2519-2528
[8]   Prevention of acute exacerbation of chronic hepatitis B infection in cancer patients receiving chemotherapy in a hepatitis B virus endemic area [J].
Hsu, Ping-I ;
Lai, Kwok-Hung ;
Cheng, Jin-Shiung ;
Kao, Sung-Shuo ;
Li, Yuan-Rung ;
Sun, Wei-Chih ;
Chen, Wen-Chi ;
Lin, Kung-Hung ;
Shin, Chih-An ;
Chiang, Po-Hung ;
Li, Yun-Da ;
Ou, Wei-Ting ;
Chen, Hui-Chun ;
Yu, Hsien-Chung .
HEPATOLOGY, 2015, 62 (02) :387-396
[9]   Hepatitis C Virus Screening in Patients With Cancer Receiving Chemotherapy [J].
Hwang, Jessica P. ;
Suarez-Almazor, Maria E. ;
Torres, Harrys A. ;
Palla, Shana L. ;
Huang, Donna S. ;
Fisch, Michael J. ;
Lok, Anna S. F. .
JOURNAL OF ONCOLOGY PRACTICE, 2014, 10 (03) :E167-E174
[10]   Incidence of hepatitis virus infection and severe liver dysfunction in patients receiving chemotherapy for hematologic malignancies [J].
Kawatani, T ;
Suou, T ;
Tajima, F ;
Ishiga, K ;
Omura, H ;
Endo, A ;
Ohmura, H ;
Ikuta, Y ;
Idobe, Y ;
Kawasaki, H .
EUROPEAN JOURNAL OF HAEMATOLOGY, 2001, 67 (01) :45-50